logo
Share SHARE
FONT-SIZE Plus   Neg

PharmAthene Says FDA Places SparVax RPA Anthrax Vaccine Program On Clinical Hold

PharmAthene Inc. (PIP) has received notification from the U.S. Food and Drug Administration or FDA that its SparVax rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the company would get a letter containing the details of the basis for the clinical hold within 30 days.

The company, during this period, would continue to provide the agency with analytical data from its recently produced GMP lot of material. The trial, which was expected to commence by the year end, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
TerraForm Global, Inc., an operator of clean energy power plants, said Monday that it has signed an exclusivity agreement with Brookfield Asset Management Inc. to negotiate a potential business combination between them. Shares of TerraForm Global are gaining more than 6 percent in pre-market activity following the announcement. Fast food giant McDonald's Corp. (MCD) on Monday reported a 1 percent decline in profit for the fourth quarter from last year on lower revenues due to the impact of refranchising. However, both revenue and earnings per share beat analysts' expectations. The Oak Brook, Illinois-based hamburger chain... U.S. authorities are investigating Yahoo Inc. for not disclosing the two massive data breaches sooner to investors, the Wall Street Journal reported, citing people familiar with the matter. It is expected that such a move could help clarify the timeline for companies to reveal such hacks.
comments powered by Disqus
Follow RTT